P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073
Title:
P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073
Author:
Sangro, B. Numata, K. Huang, Y. Gomez-Martin, C. Hiraoka, A. Moriguchi, M. Shen, Y. Horvath, A. Feely, W. Young, T. Neely, J. Kudo, M.